COVID-19 vaccinations for kids and teenagers: What we know and don't know
Editor's note: The Pfizer/BioNTech COVID-19 vaccine was fully approved by the FDA on August 23, 2021, for anyone 16 years of age and older. As more information is gathered, children between the ages of 12 and 15 may continue to receive this vaccination under emergency use authorization.
Vaccines have been hailed as a crucial strategy to halt and eventually eliminate the COVID-19 pandemic. Millions of adult Americans receive one of the approved vaccines every day, which have been shown to be very successful in preventing serious illnesses that could otherwise result in hospital stays and fatalities. The majority of Americans over 65 have received all recommended vaccinations, safeguarding the most vulnerable members of our society.
My answers to the following questions, as an expert in infectious diseases, are predicated on our current understanding of infection and vaccinations in children and adolescents. As research is conducted and our knowledge grows, we will need to keep filling in the gaps.
What is known about the effects of COVID-19 on kids and teenagers?
The majority of pediatric COVID-19 infections are either mild or show no symptoms at all. Nonetheless, a tiny portion of children who are infected
develop MIS-C, a severe inflammatory illness, two to six weeks after contracting COVID-19. Even youngsters with minimal symptoms or none at all may experience this.
become quite ill and require intensive treatment or hospitalization.
COVID-19 infection has claimed the lives of more than 400 children. That exceeds the number of pediatric fatalities during the most worst flu season in the previous twenty years.
One of the main motivations of children's vaccination research is to prevent these consequences. Additionally, immunizing children will be essential to reaching a population-wide level of immunity, or "herd immunity," that is adequate to halt the spread of harmful variations and stop the pandemic.
What is currently known regarding teen COVID-19 vaccinations?
Children and teenagers 12 years of age and older are permitted to utilize the Pfizer/BioNTech vaccination.
People who are 18 years of age or older are permitted to utilize the Johnson & Johnson and Moderna vaccinations.
These permissions were based on information from individuals of these ages who took part in randomized
placebo-controlled studies that proved these vaccines' effectiveness and safety.
Efficacy quantifies a vaccine's effectiveness under carefully regulated trial conditions.
When a vaccine is administered to members of the community outside of a research, its effectiveness is measured.
Children and teenagers 12 years of age and older can obtain the COVID-19 vaccine through the same sources that adults have had access to thus far, as states increase eligibility. Vaccination locations may differ depending on your state and place of healthcare. Check your state board of health or the searchable map on VaccineFinder.
The following are examples of vaccine research that has been completed or is currently in progress:
A trial involving children aged 12 to 15 has been concluded by Pfizer/BioNTech. The vaccination schedule and dosage utilized in this research were the same as those for adults: two shots spaced three weeks apart. The vaccination was 100% effective in preventing mild to severe illness in this age range, produced robust antibody responses, and was safe and well tolerated. After assessing the trial findings, the FDA approved this vaccine for use in this age group. For children 12 years of age and up, the American Academy of Pediatrics and the CDC both advise vaccination.
Moderna finished recruiting 12 to 17-year-olds for a comparable study that used the same dosage and timing as for adults—two injections spaced four weeks apart. In the coming months, data from this trial should be available.
For a limited group of 16–17-year-olds, Johnson and Johnson has begun a vaccination experiment. The experiment will continue with children aged 12 to 15 if the vaccination is found to be safe and effective in that age range.
What about younger children's COVID-19 vaccine trials?
Both Moderna and Pfizer/BioNTech have started testing in kids ages six months to eleven.
Each of these trials will start with doses that are lower than those administered to adults, teens, and older children. This enables researchers to identify a dose that is both well tolerated and still produces significant antibody responses in younger children.
Larger numbers of kids in these age groups will be enrolled in placebo-controlled trials to assess the effectiveness of these vaccines once the dose is determined.
It will take some time to complete all of these tasks without sacrificing safety. Younger children will probably have access to immunizations as early as late 2021 or early 2022.
What is still unknown about COVID-19 vaccinations for kids and teenagers?
It will be necessary to monitor the duration of vaccine-induced immunity against COVID-19 infection in children throughout time. Experts will use the results of these research to determine whether youngsters may get COVID-19 booster shots in the future.
The effect of these vaccines on preventing children from contracting COVID-19 variations will need to be assessed by researchers. However, there is no biological basis for anticipating that vaccination coverage of variations would differ between adults and children.
Editor's note: The Pfizer/BioNTech COVID-19 vaccine was fully approved by the FDA on August 23, 2021, for anyone 16 years of age and older. As more information is gathered, children between the ages of 12 and 15 may continue to receive this vaccination under emergency use authorization.
Vaccines have been hailed as a crucial strategy to halt and eventually eliminate the COVID-19 pandemic. Millions of adult Americans receive one of the approved vaccines every day, which have been shown to be very successful in preventing serious illnesses that could otherwise result in hospital stays and fatalities. The majority of Americans over 65 have received all recommended vaccinations, safeguarding the most vulnerable members of our society.
My answers to the following questions, as an expert in infectious diseases, are predicated on our current understanding of infection and vaccinations in children and adolescents. As research is conducted and our knowledge grows, we will need to keep filling in the gaps.
What is known about the effects of COVID-19 on kids and teenagers?
The majority of pediatric COVID-19 infections are either mild or show no symptoms at all. Nonetheless, a tiny portion of children who are infected
develop MIS-C, a severe inflammatory illness, two to six weeks after contracting COVID-19. Even youngsters with minimal symptoms or none at all may experience this.
become quite ill and require intensive treatment or hospitalization.
COVID-19 infection has claimed the lives of more than 400 children. That exceeds the number of pediatric fatalities during the most worst flu season in the previous twenty years.
One of the main motivations of children's vaccination research is to prevent these consequences. Additionally, immunizing children will be essential to reaching a population-wide level of immunity, or "herd immunity," that is adequate to halt the spread of harmful variations and stop the pandemic.
What is currently known regarding teen COVID-19 vaccinations?
Children and teenagers 12 years of age and older are permitted to utilize the Pfizer/BioNTech vaccination.
People who are 18 years of age or older are permitted to utilize the Johnson & Johnson and Moderna vaccinations.
These permissions were based on information from individuals of these ages who took part in randomized
placebo-controlled studies that proved these vaccines' effectiveness and safety.
Efficacy quantifies a vaccine's effectiveness under carefully regulated trial conditions.
When a vaccine is administered to members of the community outside of a research, its effectiveness is measured.
Children and teenagers 12 years of age and older can obtain the COVID-19 vaccine through the same sources that adults have had access to thus far, as states increase eligibility. Vaccination locations may differ depending on your state and place of healthcare. Check your state board of health or the searchable map on VaccineFinder.
The following are examples of vaccine research that has been completed or is currently in progress:
A trial involving children aged 12 to 15 has been concluded by Pfizer/BioNTech. The vaccination schedule and dosage utilized in this research were the same as those for adults: two shots spaced three weeks apart. The vaccination was 100% effective in preventing mild to severe illness in this age range, produced robust antibody responses, and was safe and well tolerated. After assessing the trial findings, the FDA approved this vaccine for use in this age group. For children 12 years of age and up, the American Academy of Pediatrics and the CDC both advise vaccination.
Moderna finished recruiting 12 to 17-year-olds for a comparable study that used the same dosage and timing as for adults—two injections spaced four weeks apart. In the coming months, data from this trial should be available.
For a limited group of 16–17-year-olds, Johnson and Johnson has begun a vaccination experiment. The experiment will continue with children aged 12 to 15 if the vaccination is found to be safe and effective in that age range.
What about younger children's COVID-19 vaccine trials?
Both Moderna and Pfizer/BioNTech have started testing in kids ages six months to eleven.
Each of these trials will start with doses that are lower than those administered to adults, teens, and older children. This enables researchers to identify a dose that is both well tolerated and still produces significant antibody responses in younger children.
Larger numbers of kids in these age groups will be enrolled in placebo-controlled trials to assess the effectiveness of these vaccines once the dose is determined.
It will take some time to complete all of these tasks without sacrificing safety. Younger children will probably have access to immunizations as early as late 2021 or early 2022.
What is still unknown about COVID-19 vaccinations for kids and teenagers?
It will be necessary to monitor the duration of vaccine-induced immunity against COVID-19 infection in children throughout time. Experts will use the results of these research to determine whether youngsters may get COVID-19 booster shots in the future.
The effect of these vaccines on preventing children from contracting COVID-19 variations will need to be assessed by researchers. However, there is no biological basis for anticipating that vaccination coverage of variations would differ between adults and children.